Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38.
Abstract
BACKGROUND
Pituitary adenylate cyclase activating peptide-38 (PACAP-38) has been shown to induce migraine in migraineurs, whereas the
related peptide vasoactive intestinal peptide (VIP) does not. In the present study we examine the hypothesis that PACAP-38
and its truncated version PACAP-27 but not VIP cause degranulation of mast cells in peritoneum and in dura mater.
METHODS
The degranulatory effects of PACAP-38, PACAP-27 and VIP were investigated by measuring the amount of N-acetyl-β-hexosaminidase
released from isolated peritoneal mast cells and from dura mater attached to the skull of the rat in vitro. In peritoneal
mast cells N-truncated fragments of PACAP-38 (PACAP(6-38), PACAP(16-38) and PACAP(28-38)) were also studied. To investigate
transduction pathways involved in mast cell degranulation induced by PACAP-38, PACAP-27 and VIP, the phospholipase C inhibitor
U-73122 and the adenylate cyclase inhibitor SQ 22536 were used.
RESULTS
The peptides induced degranulation of isolated peritoneal mast cells of the rat with the following order of potency: PACAP-38
= PACAP(6-38) = PACAP(16-38) » PACAP-27 = VIP = PACAP(28-38). In the dura mater we found that 10(-5) M PACAP-38 was significantly
more potent in inducing mast cell degranulation than the same concentration of PACAP-27 or VIP. Inhibition of intracellular
mechanisms demonstrated that PACAP-38-induced degranulation is mediated by the phospholipase C pathway. Selective blockade
of the PAC(1) receptor did not attenuate degranulation.
CONCLUSION
These findings correlate with clinical studies and support the hypothesis that mast cell degranulation is involved in PACAP-induced
migraine. PACAP-38 has a much stronger degranulatory effect on rat peritoneal and dural mast cells than VIP and PACAP-27.
The difference in potency between PACAP-38- and PACAP-27/VIP-induced peritoneal mast cell degranulation is probably not related
to the PAC(1) receptor but is caused by a difference in efficacy on phospholipase C.
Links
Authors
Baun M, Pedersen MH, Olesen J, Jansen-Olesen I
Institution
Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.
Source
Cephalalgia : an international journal of headache 32:4 2012 Mar pg 337-45MeSH
AnimalsCell Degranulation
Disease Models, Animal
Dura Mater
Male
Mast Cells
Migraine Disorders
Peptides
Pituitary Adenylate Cyclase-Activating Polypeptide
Rats
Rats, Sprague-Dawley
Vasoactive Intestinal Peptide
Vasodilator Agents
Pub Type(s)
Journal ArticleResearch Support, Non-U.S. Gov't
Language
eng
PubMed ID
22421901
Log In

